14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
DXCM vs PEN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Penumbra, Inc. (PEN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas PEN carries 52.2/100 (HOLD) at $319.12 (53.1x Forward P/E, 12.1% operating margin).
Composite vs. Pillar Nuance: While PEN currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. DXCM 50.8/100 HOLD), DXCM captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (24.0% vs. 12.1% operating margin) and revenue trajectory (+11.2% vs. +15.6% YoY).
Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile PEN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 45.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $12.6B market capitalization and 12.1% operating margin.
OpEx & R&D Reinvestment55.9% of Rev ($872M)
90D Engineering Disclosures0 Published
Investor FAQ DXCM vs PEN Key Questions & Quantitative Answers
As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Penumbra, Inc. (PEN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas PEN carries 52.2/100 (HOLD) at $319.12 (53.1x Forward P/E, 12.1% operating margin). Composite vs. Pillar Nuance: While PEN currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. DXCM 50.8/100 HOLD), DXCM captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (24.0% vs. 12.1% operating margin) and revenue trajectory (+11.2% vs. +15.6% YoY). Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile PEN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 45.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DXCM leads the Growth & Scale pillar: DXCM posts +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin), compared with PEN at +15.6% YoY revenue growth and -8.5% YoY earnings growth on $1.56B TTM revenue (68.0% gross margin, 12.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DXCM cumulative revenue shifted +352.4% while PEN shifted +218.2%. In operating R&D and SG&A reinvestment, DXCM deploys 39.4% of Rev ($2.01B) (0 90-day corporate R&D disclosures) versus 55.9% of Rev ($872M) (0 disclosures) for PEN.
DXCM screens cheaper on headline valuation multiples. DXCM trades at 25.3x Forward P/E, 31.6x Trailing P/E, 1.30x PEG, and 5.9x EV/Revenue (33.9% FCF margin), whereas PEN trades at 53.1x Forward P/E, 80.6x Trailing P/E, 3.61x PEG, and 8.1x EV/Revenue (12.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXCM (37.7% ROE) versus PEN (10.7% ROE) capital efficiency.
In options market volatility and institutional positioning, DXCM carries 63.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.48x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 43% Vol realized risk). By comparison, PEN carries 207.7% implied volatility (96th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.10β · 10% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.